DeepMed Research

United Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1996-01-01

Employees: -

Market Cap: $15.5B

Website: http://www.unither.com

Clinical Trials

Safety and Efficacy of Inhaled Treprostinil in Patients With PAH

Phase 3

Withdrawn

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Inhaled treprostinil
Drug: Placebo

First Posted Date: 2012-03-19

Last Posted Date: 2012-03-26

Lead Sponsor: United Therapeutics

Registration Number: NCT01557647

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Phase 2

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: UT-15C SR
Drug: Tyvaso Inhalation Solution

First Posted Date: 2011-11-22

Last Posted Date: 2023-12-27

Lead Sponsor: United Therapeutics

Target Recruit Count: 18

Registration Number: NCT01477333

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 3 locations

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: inhaled prostacyclin
Drug: prostacyclin
Drug: subcutaneous and intravenous prostacyclin
Drug: oral ERA
Drug: oral PDE5 inhibitors

First Posted Date: 2010-12-24

Last Posted Date: 2016-02-17

Lead Sponsor: United Therapeutics

Target Recruit Count: 1333

Registration Number: NCT01266265

Locations: 🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Northwestern Medical Center, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

and more 85 locations

A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers

Phase 1

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: treprostinil diethanolamine

First Posted Date: 2010-07-29

Last Posted Date: 2010-10-13

Lead Sponsor: United Therapeutics

Target Recruit Count: 24

Registration Number: NCT01172496

Locations: 🇺🇸
PPD Development, Austin, Texas, United States

Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities

Phase 1

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Treprostinil diethanolamine

First Posted Date: 2010-07-19

Last Posted Date: 2011-04-19

Lead Sponsor: United Therapeutics

Target Recruit Count: 64

Registration Number: NCT01165476

Locations: 🇺🇸
PPD Development, Austin, Texas, United States

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

Phase 1

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Treprostinil diethanolamine

First Posted Date: 2010-06-30

Last Posted Date: 2010-08-23

Lead Sponsor: United Therapeutics

Target Recruit Count: 36

Registration Number: NCT01153386

Locations: 🇺🇸
PPD Development, Austin, Texas, United States

The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil

Phase 1

Completed

Conditions: Pulmonary Arterial Hypertension
Renal Dysfunction

Interventions: Drug: UT-15C SR (treprostinil diethanolamine)

First Posted Date: 2010-05-27

Last Posted Date: 2012-05-17

Lead Sponsor: United Therapeutics

Target Recruit Count: 16

Registration Number: NCT01131845

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension

Phase 2

Completed

Conditions: Pulmonary Hypertension

Interventions: Drug: UT-15C

First Posted Date: 2010-04-16

Last Posted Date: 2016-05-27

Lead Sponsor: United Therapeutics

Target Recruit Count: 50

Registration Number: NCT01104870

Locations: 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸
University of California Los Angeles Pulmonary Division, Los Angeles, California, United States

and more 6 locations

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

Completed

Conditions: Pulmonary Hypertension
Pulmonary Arterial Hypertension
Portopulmonary Hypertension

Interventions: Drug: Treprostinil

First Posted Date: 2009-12-09

Last Posted Date: 2017-02-24

Lead Sponsor: United Therapeutics

Target Recruit Count: 13

Registration Number: NCT01028651

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Emory Univeristy, Atlanta, Georgia, United States

and more 1 locations

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

Phase 3

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Oral Treprostinil

First Posted Date: 2009-12-09

Last Posted Date: 2021-05-10

Lead Sponsor: United Therapeutics

Target Recruit Count: 894

Registration Number: NCT01027949

Locations: 🇩🇪
Zentrum für Lungenhochdruck Thoraxklinik am Universitätsklinikum Heidelberg, Hamburg, Germany
🇮🇹
Dipartimento di Scienze Cardiovascolari, Respiratorie e Morfologiche, Rome, Italy
🇲🇽
Unidad de Investigacion Clinica en Medicina S.C., Monterrey, Mexico

and more 131 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy